Announcement on Convening the 2025 Annual Performance Briefing
Filed with SSE · · 2 pages · Chinese
Humanwell Healthcare (Group) Co.,Ltd. on 6ix
Earlier from Humanwell Healthcare (Group) Co.,Ltd
- Announcement on Obtaining Drug Registration Certificate by Subsidiary
- Announcement on Risk Assessment Report for China Merchants Group Finance Co., Ltd.
- Announcement on Initiation of Phase II Clinical Trial for HW091077 Tablets
- Announcement on Holding Subsidiary's Passing EU GMP Compliance Inspection
- Announcement on Micafungin Sodium for Injection Obtaining US FDA Approval
Later from Humanwell Healthcare (Group) Co.,Ltd
- Announcement on Obtaining Marketing Authorization from the German Federal Institute for Drugs and Medical Devices (BfArM) for Remifentanil Hydrochloride for Injection
- Announcement on Resolutions of the 7th Meeting of the 11th Board of Directors
- Report for Q1 2026
- Announcement on Resolutions of the 1st Extraordinary General Meeting in 2026
- Announcement on RFUS-188 Injection Obtaining Notice of Approval for Drug Clinical Trial
Follow Humanwell Healthcare (Group) Co.,Ltd into a list and get an email when it puts out news.
Follow Humanwell Healthcare (Group) Co.,Ltd